• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dev Ctries . Could ischemia-modified albumin levels predict the severity of disease in SARS-CoV-2 infection?

tetano

Editor, Senior Moderator
J Infect Dev Ctries


. 2023 Aug 31;17(8):1055-1062.
doi: 10.3855/jidc.17456. Could ischemia-modified albumin levels predict the severity of disease in SARS-CoV-2 infection?

Mustafa Tanrıverdi[SUP] 1 [/SUP], Nevhiz Gündoğdu[SUP] 2 [/SUP], Necla Benlier[SUP] 3 [/SUP], Mustafa Yıldırım[SUP] 4 [/SUP], Hale Çeliktürk[SUP] 5 [/SUP], Hanifi Ayhan Özkur[SUP] 6 [/SUP], Pınar Günel Karadeniz[SUP] 7 [/SUP], Gülşen Özkan Tanrıverdi[SUP] 8 [/SUP], Hülya Çiçek[SUP] 9 [/SUP]



Affiliations
Abstract

Introduction: Ischemia-modified albumin (IMA) level increases in inflammatory conditions. We aimed to investigate the association between IMA levels and the severity of coronavirus disease 2019 (COVID-19) infection in adult patients.
Methodology: We grouped adult patients with COVID-19 infection: Group A - mild symptoms, but normal computed tomography (CT), Group B - mild/moderate illness, and Group C - severe or critical illness. We measured IMA levels at the time of diagnosis of COVID-19 infection.
Results: Mean age of the total number of patients (n = 90) was 54.43 (± 8.11) year, and 46.7% (n = 42) were female. IMA levels were highest in Group C and lowest in A (p < 0.001). The most important factor predicting COVID-19 disease severity was IMA. Type 2 diabetes was more frequent in Group C (n = 31) than in Group B (n = 30) (p = 0.042). Asthma was less frequent, and coronary artery disease was more frequent in Group C than in Group A (n = 29) and B (p = 0.009). Duration of hospitalization was highest in Group C (p < 0.001).
Conclusions: We analyzed a sample of patients with COVID-19 infection and found that IMA predicted severe COVID-19 disease. Disease severity grouping was based on patients' clinical and radiological features. IMA level measured when SARS-CoV-2 infection is diagnosed may be a useful marker in predicting likely disease severity or intensive care need.

Keywords: COVID-19; IMA; Ischemia-modified albumin; SARS-CoV-2; pandemic; severity.

 
Back
Top Bottom